|
1) Weismann RE, Tobin RW. Arterial embolism occurring during systemic heparin therapy. AMA Arch Surg. 1958; 76: 219-25; discussion 225-7
|
|
|
|
2) Rhodes GR, Dixon RH, Silver D. Heparin induced thrombocytopenia: eight cases with thrombotic-hemorrhagic complications. Ann Surg. 1977; 186: 752-8
|
|
|
|
|
|
3) Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost. 1992; 68: 95-6
|
|
|
|
|
|
4) Miyata S, Yamamoto H, Kamei M, et al. Heparin-induced thrombocytopenia clinical studies and the efficacy of argatroban in Japan. Semin Thromb Hemost. 2008; 34 suppl 1: 37-47
|
|
|
|
|
|
5) Kawano H, Toyoda K, Miyata S, et al. Heparin-induced thrombocytopenia: a serious complication of heparin therapy for acute stroke. Cerebrovascular Diseases. 2008; 26: 641-9
|
|
|
|
|
6) Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(6 Suppl): 340S-80S
|
|
|
|
|
|
7) Heparin-Induced Thrombocytopenia. 4th ed. New York: Informa Healthcare; 2007
|
|
|
|
|
|
8) Selleng S, Selleng K, Wollert HG, et al. Heparin-induced thrombocytopenia in patients requiring prolonged intensive care unit treatment after cardiopulmonary bypass. J Thromb Haemost. 2008; 6: 428-35
|
|
|
|
|
|
9) Rauova L, Poncz M, McKenzie SE, et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood. 2005; 105: 131-8
|
|
|
|
|
|
10) Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005; 106: 2710-5
|
|
|
|
|
|
11) Reilly MP, Taylor SM, Hartman NK, et al. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. Blood. 2001; 98: 2442-7
|
|
|
|
|
|
12) Rauova L, Zhai L, Kowalska MA, et al. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood. 2006; 107: 2346-53
|
|
|
|
|
|
13) Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost. 2005; 94: 132-5
|
|
|
|
|
|
14) Makhoul RG, Greenberg CS, McCann RL. Heparin-associated thrombocytopenia and thrombosis: a serious clinical problem and potential solution. J Vasc Surg. 1986; 4: 522-8
|
|
|
|
|
|
15) Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001; 344: 1286-92
|
|
|
|
|
|
16) Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med. 2001; 135: 502-6
|
|
|
|
|
|
17) Mims MP, Manian P, Rice L. Acute cardiorespiratory collapse from heparin: a consequence of heparin-induced thrombocytopenia. Eur J Haematol. 2004; 72: 366-9
|
|
|
|
|
|
18) Francis JL, Palmer GJ 3rd, Moroose R, et al. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg. 2003; 75: 17-22
|
|
|
|
|
|
19) Warkentin TE, Sheppard JA, Horsewood P, et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000; 96: 1703-8
|
|
|
|
|
|
20) Pouplard C, May MA, Regina S, et al. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. Br J Haematol. 2005; 128: 837-41
|
|
|
|
|
|
21) Warkentin TE, Roberts RS, Hirsh J, et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med. 2003; 163: 2518-24
|
|
|
|
|
|
22) Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep. 2003; 2: 148-57
|
|
|
|
|
|
23) Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006; 4: 759-65
|
|
|
|
|
|
24) Pouplard C, Gueret P, Fouassier M, et al. Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost. 2007; 5: 1373-9
|
|
|
|
|
|
25) Greinacher A, Juhl D, Strobel U, et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost. 2007; 5: 1666-73
|
|
|
|
|
|
26) Amiral J, Marfaing-Koka A, Wolf M, et al. Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood. 1996; 88: 410-6
|
|
|
|
|
|
27) Regnault V, de Maistre E, Carteaux JP, et al. Platelet activation induced by human antibodies to interleukin-8. Blood. 2003; 101: 1419-21
|
|
|
|
|
|
28) Pouplard C, Amiral J, Borg JY, et al. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol. 1999; 111: 700-6
|
|
|
|
|
|
29) Zwicker JI, Uhl L, Huang WY, et al. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost. 2004; 2: 2133-7
|
|
|
|
|
|
30) Verma AK, Levine M, Shalansky SJ, et al. Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy. 2003; 23: 745-53
|
|
|
|
|
|
31) Crowther MA, Cook DJ, Meade MO, et al. Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors. J Crit Care. 2005; 20: 348-53
|
|
|
|
|
|
32) Kadidal VV, Mayo DJ, Horne MK. Heparin-induced thrombocytopenia (HIT) due to heparin flushes: a report of three cases. J Intern Med. 1999; 246: 325-9
|
|
|
|
|
|
33) Rice L, Jackson D. Can heparin cause clotting？ Heart Lung. 1981; 10: 331-5
|
|
|
|
|
|
34) Greinacher A, Eichler P, Lubenow N, et al. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood. 2000; 96: 846-51
|
|
|
|
|
|
35) Warkentin TE, Elavathil LJ, Hayward CP, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med. 1997; 127: 804-12
|
|
|
|
|
|
36) Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2006; 355: 809-17
|
|
|
|
|
|
37) Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995; 332: 1330-5
|
|
|
|
|
|
38) Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost. 1993; 70: 554-61
|
|
|
|
|
|
39) Ichikawa M, Oue M, Okamoto A, et al. A case of heparin-induced thrombocytopenia associated with unexpected excessive argatroban anticoagulation after abdominal aortic aneurysm resection. Masui. 2006; 55: 188-92
|
|
|
|
|
40) Reichert MG, MacGregor DA, Kincaid EH, et al. Excessive argatroban anticoagulation for heparin-induced thrombocytopenia. Ann Pharmacother. 2003; 37: 652-4
|
|
|
|
|
|
41) Beiderlinden M, Treschan TA, Gorlinger K, et al. Argatroban anticoagulation in critically ill patients. Ann Pharmacother. 2007; 41: 749-54
|
|
|
|
|
|
42) Kuo KH, Kovacs MJ. Fondaparinux: a potential new therapy for HIT. Hematology. 2005; 10: 271-5
|
|
|
|
|
|
43) Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood. 2005; 106: 3791-6
|
|
|
|
|
|
44) Savi P, Chong BH, Greinacher A, et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood. 2005; 105: 139-44
|
|
|
|
|
|
45) Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med. 2007; 356: 2653-5; discussion 2653-5
|
|
|
|
|
|
46) Potzsch B, Klovekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med. 2000; 343: 515
|
|
|
|
|
|
47) Koster A, Dyke CM, Aldea G, et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg. 2007; 83: 572-7
|
|
|
|
|
|
48) Dyke CM, Aldea G, Koster A, et al. Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies. Ann Thorac Surg. 2007; 84: 836-9
|
|
|
|
|
|
49) Matsuo T, Kusano H, Wanaka K, et al. Heparin-induced thrombocytopenia in a uremic patient requiring hemodialysis: an alternative treatment and reexposure to heparin. Clin Appl Thromb Hemost. 2007; 13: 182-7
|
|
|
|
|